Hims & Hers Super Bowl ad for compounded semaglutide ignites debate over IP, patient safety, and the GLP-1 gray market

Summary

Hims & Hers aired a Super Bowl ad positioning its compounded version of semaglutide as an affordable alternative to Novo Nordisk's branded Wegovy and Ozempic, painting the weight loss drug market as rigged by a greedy healthcare system. The commercial, which featured Childish Gambino's "This Is America," prompted immediate backlash from pharma lobbying group PhRMA and a bipartisan Senate letter from Dick Durbin and Roger Marshall criticizing the ad as deceptive for failing to disclose safety risks and side effects.

The core tension centers on IP and patient safety. TJ Parker, the co-founder of PillPack (acquired by Amazon for $1 billion), pushed back hard on the strategy, arguing that Hims is "shamelessly stealing IP" while selling compounded semaglutide at roughly the same net price as the original branded drug—undercutting the Robin Hood narrative. His broader concern is compounding quality. Unlike FDA-regulated pharmaceutical manufacturing, compounding pharmacies operate with minimal barriers. A single license can cost less than $1 million to acquire, and a small operation—essentially one room with a licensed operator—can manufacture and ship injectables directly to consumers. Parker's worry that patient harm stems from this gray-market production reflects a legitimate problem: compounded peptides lack the rigorous testing and quality controls of brand-name drugs.

Hims' ability to compound semaglutide hinges on an FDA shortage designation that remains active for Novo's Ozempic and Wegovy. Federal regulations permit compounding when a drug is in short supply and deemed critical. The FDA recently declared the shortage of Eli Lilly's Zepbound over, ending legal compounding for that competitor. Novo remains on the shortage list, which is precisely what Novo wants to escape—ending the shortage would choke off Hims' compounding advantage and force the telehealth company into white-label reselling of the branded drug at lower margins.

The calculus appears to be that the revenue from rapid customer acquisition and high margins on compounded versions outweighs regulatory risk. Hims' stock has performed well, and the company seems comfortable absorbing potential future fines as a cost of market dominance. The telehealth model itself—avoiding the friction of in-person visits for sensitive conditions like obesity, erectile dysfunction, and hair loss—has proven durable. Conversion rates are likely higher than traditional pharma channels, which could sustain customer loyalty even after compounding eventually ends and Hims transitions to selling branded drugs at lower margins.

The longer game is about building a defensible customer base before supply constraints ease. Once Novo increases production enough to end the shortage, compounding will be legally curtailed. But by then, Hims will have acquired millions of customers who may stick around for the convenience of telemedicine, even if they're paying more for the branded version. The ad's timing—released early to front-run competitors—suggests Hims is racing to capture market share while the window remains open.

There is a plausible bull case: telemedicine for primary care and prescription refills could consolidate into one platform, and if Hims becomes that platform, the TAM could justify valuations in the hundreds of billions. But that outcome depends on staying out of serious regulatory trouble and on winning customer loyalty despite operating in a patent-ambiguous gray market. The company is betting that customer outcomes—people losing significant weight—will matter more than the method of manufacture. Whether that confidence is justified will become clear once outcome data accumulates and supply constraints resolve.